U.S. CTEPH Registry

Condition: Pulmonary hypertension

Eligibility

Key Inclusion Criteria

  • Patient must be a permanent resident of the United States.
  • Documentation of the following hemodynamic parameters by right heart catheterization:
    • Mean pulmonary arterial pressure (PAPm) ≥25 mm Hg at rest AND
    • Pulmonary artery wedge pressure (PAWP) ≤15 mm Hg (or >15 mmHg if justified)
  • Radiologic confirmation that chronic thromboembolic disease is the cause of the pulmonary hypertension
    • One or more mismatched perfusion defect(s) by lung ventilation/perfusion scan AND
    • Confirmation of chronic thromboembolic disease by evidence of bands/webs, vessel narrowing or occlusion seen on CT pulmonary angiogram (CTA), conventional angiography or MR angiography (MRA)
  • Patients must be diagnosed with CTEPH within six months of being considered for study eligibility (signing of consent to participate). The date of diagnosis will be defined as when both hemodynamic criteria have been met and chronic thromboembolic disease is confirmed to be the cause of the pulmonary hypertension by an abnormal V/Q scan and the presence of chronic thromboembolic disease on CTA, MRA or pulmonary angiography. Hemodynamic and radiologic criteria can be met at separate time points; the most recently met criteria time point will be defined as the date of diagnosis.
  • Prior to enrollment, all subjects must have the diagnosis of CTEPH confirmed by the Adjudication Committee.

Key Exclusion Criteria

  • Patients unwilling or unable to provide written consent for participation in the study. Appropriate surrogate consent will be obtained for pediatric patients as defined by each investigational site's IRB.
  • Patients with an underlying medical disorder with an anticipated life expectancy less than two years
  • Patient who do not meet inclusion criteria including:
    • Have not had documentation of hemodynamic criteria by right heart catheterization as outlined in the inclusion criteria
    • Do not have radiologic confirmation of chronic thromboembolic disease as outlined in the inclusion criteria
    • Meet the criteria for inclusion into WHO Groups I, II, III or V

Full Study Name

U.S. CTEPH Registry

Summary

This purpose of this research registry is to collect clinical information about patients diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH). Researchers aim to learn more about the CTEPH disease process and treatment of patients by sharing information among pulmonary hypertension centers throughout the U.S.

The development of a national registry is an important element in the advancement of the understanding of CTEPH and improvement in the care of patients with this debilitating disease.

IRB No.

39670

Principal Investigator

Victor Tapson, MD

Contact
Lucy Garcia
Phone: 310-248-7134
Email: lucilla.garcia@cshs.org